JP2023520770A5 - - Google Patents

Info

Publication number
JP2023520770A5
JP2023520770A5 JP2022558131A JP2022558131A JP2023520770A5 JP 2023520770 A5 JP2023520770 A5 JP 2023520770A5 JP 2022558131 A JP2022558131 A JP 2022558131A JP 2022558131 A JP2022558131 A JP 2022558131A JP 2023520770 A5 JP2023520770 A5 JP 2023520770A5
Authority
JP
Japan
Prior art keywords
dose
serum
level
deposition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520770A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024345 external-priority patent/WO2021195488A1/en
Publication of JP2023520770A publication Critical patent/JP2023520770A/ja
Publication of JP2023520770A5 publication Critical patent/JP2023520770A5/ja
Pending legal-status Critical Current

Links

JP2022558131A 2020-03-27 2021-03-26 肺浮腫又は肺炎症を治療するための組成物及び方法 Pending JP2023520770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000939P 2020-03-27 2020-03-27
US63/000,939 2020-03-27
PCT/US2021/024345 WO2021195488A1 (en) 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation

Publications (2)

Publication Number Publication Date
JP2023520770A JP2023520770A (ja) 2023-05-19
JP2023520770A5 true JP2023520770A5 (https=) 2024-06-24

Family

ID=77892642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558131A Pending JP2023520770A (ja) 2020-03-27 2021-03-26 肺浮腫又は肺炎症を治療するための組成物及び方法

Country Status (7)

Country Link
US (1) US12569459B2 (https=)
EP (1) EP4126104A4 (https=)
JP (1) JP2023520770A (https=)
CN (1) CN115551569A (https=)
CA (1) CA3177377A1 (https=)
MX (1) MX2022011821A (https=)
WO (1) WO2021195488A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024778A1 (en) * 2023-07-27 2025-01-30 Regents Of The University Of Minnesota Medical treatment system and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US8309080B2 (en) 2007-12-06 2012-11-13 Naidu Lp Metallo-protein and tocotrienol (MP-T3) compositions and uses thereof
US8304401B2 (en) 2008-09-02 2012-11-06 Trustees Of Dartmouth College Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
WO2010124372A1 (en) * 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
CN107041879A (zh) 2017-04-01 2017-08-15 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防肺部疾病的药物中的应用
MX2020007971A (es) 2018-01-31 2020-09-09 Univ Minnesota Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
WO2019178023A1 (en) 2018-03-12 2019-09-19 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome

Similar Documents

Publication Publication Date Title
Zoltowska et al. The interleukin‐33 receptor ST 2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma
HRP20150290T1 (hr) Metoda lijeäśenja karcinoma prostate s gnrh antagonistom degareliksom
Tharakan et al. Reversal of cigarette smoke extract‐induced sinonasal epithelial cell barrier dysfunction through Nrf2 activation
JP2014503593A5 (https=)
JP2023520770A5 (https=)
JP2018505183A5 (https=)
RU2008141218A (ru) Способ дифференциальной диагностики инфильтративного туберкулеза и периферического рака легких
Kumar et al. A Comparative study of the clinical characteristics of the first and second waves of COVID-19 in a tertiary care centre of North India
Carfagna et al. Occurrence of influenza A (H1N1) v infection and concomitant invasive pulmonary aspergillosis in a patient with chronic obstructive pulmonary disease.
Duran et al. The effect of zinc supplementation on cigarette smoke-induced nephrotoxicity in rats
Lai et al. Comparison of nebulized budesonide with intravenous dexamethasone in the treatment of young children hospitalized with acute asthma
Yao et al. C68 IMMUNE CELL INTERACTIONS IN COPD: Increased Neutrophil Gelatinase-Associated Lipocalin (ngal) Promotes Airway Remodeling In COPD
Ohara Fatal acute exacerbation of idiopathic pulmonary fibrosis: case report
Li et al. Cluster analysis of chronic obstructive pulmonary disease (COPD) related phenotypes in the SubPopulations And InteRmediate Outcome Measures In COPD Study (SPIROMICS)
CHEN et al. Effects of inhaled nitric oxide on intrapulmonarynitric oxide production and expression of plasminogen activator inhibitor-1 in lipopolysaccharide-induced acute lung injury
CAO et al. Expression of Gq in bronchopulmonary tissues in rats after inhalation of cigarette smoke
Zhang et al. The Iron Chelator, DIBI, Reduces Bacterial Load and Inflammation in Experimental Lung Infection
Asakura et al. S1p Receptor Modulation Expands Cd11b+ gr-1+ Cells And Inhibits Lymphocyte Infiltration In The Lungs And Ameliorate Murine Pulmonary Emphysema
Bayat et al. High Resolution CT in Children with Cystic Fibrosis: Correlation between Lung Attenuation, Radiological Score and Respiratory Function.
Lee et al. Toxicogenomic study of PHMG-induced pulmonary toxicity in rats
Liu et al. The Deletion Of Cxcr3 Gene Can't Prevent From COPD After Long Term Of Cigarette Smoking Exposure In Mice
Romberger et al. Inhibition Of EGF Receptor Signaling Decreases Agricultural Dust-Mediated Lung Inflammatory Responses In Vivo And In Vitro
Chang et al. A77 CHANGES IN THE LUNG DUE TO DIETARY AND ENVIRONMENTAL EXPOSURES: Increased Airway Narrowing Capacity Of Bronchial Segments From Preterm Lambs In An Ovine Model Of Chorioamnionitis
이정대 et al. ¹H-NMR-based toxicometabolomics study of PHMG-p-induced pulmonary damage in mice
Koumoundouros et al. Increased baseline airway resistance and smooth muscle content in sheep exposed to repeated challenges of house dust mite